KR100856353B1 - 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들,상기 조절인자들의 합성 및 상기 조절인자들의 사용 방법 - Google Patents

신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들,상기 조절인자들의 합성 및 상기 조절인자들의 사용 방법 Download PDF

Info

Publication number
KR100856353B1
KR100856353B1 KR1020017014545A KR20017014545A KR100856353B1 KR 100856353 B1 KR100856353 B1 KR 100856353B1 KR 1020017014545 A KR1020017014545 A KR 1020017014545A KR 20017014545 A KR20017014545 A KR 20017014545A KR 100856353 B1 KR100856353 B1 KR 100856353B1
Authority
KR
South Korea
Prior art keywords
alkyl
branched
straight
halogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017014545A
Other languages
English (en)
Korean (ko)
Other versions
KR20020028878A (ko
Inventor
마이클 펄래디노
임마누엘 에이 티오도라키스
Original Assignee
니리어스 파마슈티컬즈, 인크.
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니리어스 파마슈티컬즈, 인크., 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 니리어스 파마슈티컬즈, 인크.
Publication of KR20020028878A publication Critical patent/KR20020028878A/ko
Application granted granted Critical
Publication of KR100856353B1 publication Critical patent/KR100856353B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/28—Unsaturated compounds polycyclic
    • C07C61/29—Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/35—Unsaturated compounds having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020017014545A 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들,상기 조절인자들의 합성 및 상기 조절인자들의 사용 방법 Expired - Fee Related KR100856353B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13429599P 1999-05-14 1999-05-14
US60/134,295 1999-05-14
US18685300P 2000-03-03 2000-03-03
US60/186,853 2000-03-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020067025785A Division KR100840925B1 (ko) 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법
KR1020067020613A Division KR20060110013A (ko) 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법

Publications (2)

Publication Number Publication Date
KR20020028878A KR20020028878A (ko) 2002-04-17
KR100856353B1 true KR100856353B1 (ko) 2008-09-04

Family

ID=26832188

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020017014545A Expired - Fee Related KR100856353B1 (ko) 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들,상기 조절인자들의 합성 및 상기 조절인자들의 사용 방법
KR1020067025785A Expired - Fee Related KR100840925B1 (ko) 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법
KR1020067020613A Withdrawn KR20060110013A (ko) 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020067025785A Expired - Fee Related KR100840925B1 (ko) 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법
KR1020067020613A Withdrawn KR20060110013A (ko) 1999-05-14 2000-05-12 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법

Country Status (17)

Country Link
US (3) US6365768B1 (enExample)
EP (2) EP1591437B1 (enExample)
JP (2) JP5059996B2 (enExample)
KR (3) KR100856353B1 (enExample)
CN (1) CN1361760A (enExample)
AT (2) ATE449754T1 (enExample)
AU (2) AU783372B2 (enExample)
BR (1) BR0011522A (enExample)
CA (1) CA2372962C (enExample)
DE (2) DE60036101T2 (enExample)
DK (1) DK1178952T5 (enExample)
ES (2) ES2337264T3 (enExample)
IL (3) IL146221A0 (enExample)
MX (1) MXPA01011613A (enExample)
NZ (3) NZ540001A (enExample)
PT (2) PT1178952E (enExample)
WO (1) WO2000073253A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4615710B2 (ja) * 1998-01-26 2011-01-19 サエ ハン ファーム．シーオー．，エルティーディー． ジテルペン誘導体及びこれらを含む消炎鎮痛剤
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7119223B2 (en) * 1999-05-14 2006-10-10 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
DK1178952T5 (da) * 1999-05-14 2008-03-17 Univ California Hidtil ukendte modulatorer af interleukin 1 og tumornekrosefaktor a, syntese af nævnte modulatorer og fremgangsmåder til anvendelse af nævnte modulatorer
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002079137A1 (en) * 2001-03-28 2002-10-10 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use
US20030087334A1 (en) * 2001-04-02 2003-05-08 Libraria, Inc. Method of flexibly generating diverse reaction chemistries
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
JP2005532992A (ja) * 2002-01-25 2005-11-04 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 肝炎治療剤及び予防剤または肝臓保護剤として有用なソムオガルピ（ＡｃａｎｔｈｏｐａｎａｘＫｏｒｅａｎｕｍ）抽出物
WO2005084141A2 (en) * 2004-03-03 2005-09-15 Korea Research Institute Of Bioscience And Biotechnology Novel abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease
EP1912932B1 (en) * 2005-07-21 2012-05-02 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP1925301A1 (en) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
US7875853B2 (en) * 2007-07-23 2011-01-25 Honeywell International Inc. Low-cost PIR scanning mechanism
LT2252283T (lt) 2008-01-11 2019-03-25 Reata Pharmaceuticals, Inc. Sintetiniai triterpenoidai ir jų panaudojimo būdai gydant ligą
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009129545A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110293653A1 (en) * 2010-03-11 2011-12-01 University Of Massachusetts Antagonists of mir-155 for the treatment of inflammatory liver disease
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
EP2632892B1 (en) * 2010-10-27 2014-07-30 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Diterpenoid derivatives endowed of biological properties
AU2011338548B2 (en) * 2010-12-06 2016-09-29 The Penn State Research Foundation Compositions and methods relating to proliferative diseases
HUE038046T2 (hu) 2010-12-17 2018-09-28 Reata Pharmaceuticals Inc Antioxidáns gyulladáscsökkentõ pirazolil és pirimidinil triciklusos enonok
CN103619866B (zh) 2011-03-11 2016-06-22 里亚塔医药公司 C4-一甲基三萜系化合物的衍生物及其使用方法
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CR20150117A (es) 2012-09-10 2016-10-10 Reata Pharmaceuticals Inc Derivados c17-alcandilo y alquendilo del ácido oleanólico y sus métodos de uso
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
MA46749A (fr) 2016-11-08 2019-09-18 Reata Pharmaceuticals Inc Méthodes de traitement du syndrome d'alport à l'aide d'un méthyle de bardoxolone ou d'analogues de ce dernier
CN106928095A (zh) * 2017-03-14 2017-07-07 华东师范大学 氰基烯酮类三环二萜类似物及其制备方法和应用
US10463631B2 (en) * 2017-06-12 2019-11-05 University Of South Carolina Pimarane diterpenoids for use in wound healing and angiogenesis
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
KR102891865B1 (ko) 2019-07-19 2025-11-26 리아타 파마슈티컬즈, 아이엔씨. C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034300A1 (en) * 1994-06-13 1995-12-21 Korea Institute Of Science And Technology Process for the preparation of acanthoic acid and pharmaceutical composition comprising same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5212708B2 (enExample) 1974-05-14 1977-04-08
JPS522910B2 (enExample) 1974-05-17 1977-01-25
GB1452053A (en) 1974-08-28 1976-10-06 Nippon Shinyaku Co Ltd Abietamide derivatives and a method for the preparation thereof
US4874891A (en) 1986-05-01 1989-10-17 Washington University Open "D" ring hormone analogs
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
WO1991013855A1 (en) 1990-03-06 1991-09-19 Otsuka Pharmaceutical Co., Ltd. Phenanthrene derivative
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
ES2248793T3 (es) 1993-10-01 2006-03-16 Roche Palo Alto Llc Suspensiones orales de alta dosis de mofetil micofenolato.
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
JP4615710B2 (ja) 1998-01-26 2011-01-19 サエ ハン ファーム．シーオー．，エルティーディー． ジテルペン誘導体及びこれらを含む消炎鎮痛剤
US6051590A (en) 1999-05-13 2000-04-18 Merck & Co., Inc. Immunosuppressant tricyclic compounds
DK1178952T5 (da) 1999-05-14 2008-03-17 Univ California Hidtil ukendte modulatorer af interleukin 1 og tumornekrosefaktor a, syntese af nævnte modulatorer og fremgangsmåder til anvendelse af nævnte modulatorer
WO2002079137A1 (en) 2001-03-28 2002-10-10 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034300A1 (en) * 1994-06-13 1995-12-21 Korea Institute Of Science And Technology Process for the preparation of acanthoic acid and pharmaceutical composition comprising same

Also Published As

Publication number Publication date
IL146221A0 (en) 2002-07-25
PT1591437E (pt) 2010-03-04
CN1361760A (zh) 2002-07-31
CA2372962A1 (en) 2000-12-07
IL182272A0 (en) 2007-07-24
HK1084657A1 (en) 2006-08-04
BR0011522A (pt) 2002-06-04
KR20060135080A (ko) 2006-12-28
EP1178952B1 (en) 2007-08-22
DK1178952T3 (da) 2008-01-28
NZ540001A (en) 2007-06-29
AU2006200240B2 (en) 2009-05-28
DE60036101D1 (de) 2007-10-04
IL182272A (en) 2010-05-31
AU5013300A (en) 2000-12-18
EP1178952A1 (en) 2002-02-13
IL146221A (en) 2007-07-04
US20030040640A1 (en) 2003-02-27
US6365768B1 (en) 2002-04-02
US20050209325A1 (en) 2005-09-22
ATE370928T1 (de) 2007-09-15
JP2012211162A (ja) 2012-11-01
ES2337264T3 (es) 2010-04-22
US7342125B2 (en) 2008-03-11
MXPA01011613A (es) 2003-10-14
CA2372962C (en) 2008-04-08
ES2295031T3 (es) 2008-04-16
DE60036101T2 (de) 2008-05-15
AU2006200240A1 (en) 2006-02-16
WO2000073253A1 (en) 2000-12-07
AU783372B2 (en) 2005-10-20
KR20020028878A (ko) 2002-04-17
KR100840925B1 (ko) 2008-06-24
US6881857B2 (en) 2005-04-19
DK1178952T5 (da) 2008-03-17
JP2003500464A (ja) 2003-01-07
EP1591437A3 (en) 2006-03-08
EP1591437A2 (en) 2005-11-02
KR20060110013A (ko) 2006-10-23
NZ515675A (en) 2004-06-25
ATE449754T1 (de) 2009-12-15
JP5059996B2 (ja) 2012-10-31
PT1178952E (pt) 2007-12-04
DE60043400D1 (de) 2010-01-07
EP1591437B1 (en) 2009-11-25
NZ529505A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
KR100856353B1 (ko) 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들,상기 조절인자들의 합성 및 상기 조절인자들의 사용 방법
KR20080035650A (ko) 인터루킨―1 및 종양괴사인자―ａ 조정자들, 이러한조정자들의 합성 및 이들의 사용 방법
HK1084657B (en) Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
US7119223B2 (en) Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
WO2002079137A1 (en) Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use
HK1048110A (en) NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-α MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS
HK1156929A (en) Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20110719

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120802

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130829

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130829